Filter results
You can narrow down the results using the filters
Topic
- (-) Assessed listed medicines (2)
- Advertising (202)
- COVID-19 (111)
- Medicines safety (88)
- COVID-19 vaccines (63)
- Prescription medicines (61)
- Regulatory compliance (60)
- Medical devices safety (34)
- Medicines (32)
- Legislation (31)
- Medical devices (29)
- Manufacturing (18)
- Scheduling (17)
- Complementary medicines (16)
- Unapproved therapeutic goods (14)
- Safety (12)
- Therapeutic goods regulation (12)
- Listed medicines (10)
- Medicinal cannabis hub (10)
- OTC medicines (10)
- Labelling and packaging (9)
- Nicotine vaping products hub (9)
- Shortages (9)
- Sunscreens (7)
- Biologicals (6)
- Import and export (6)
- Non-prescription medicines (6)
- Australian Register of Therapeutic Goods (ARTG) (5)
- Alert/Advisory (4)
- Compliance and enforcement hub (3)
- Advisory bodies and committees (2)
- Fees and payments (2)
- In Vitro Diagnostic medical devices (IVDs) (2)
- Weight loss products (2)
- Biological medicines (1)
- Blood and blood components (1)
- Blood safety (1)
- Clinical trials (1)
- Cosmetics (1)
- Other therapeutic goods (1)
- Prescription opioids hub (1)
- Travelling with health products (1)
- Unique Device Identification (UDI) Hub (1)
Audience
Type
Search
2 result(s) found, displaying 1 to 2
- NewsChanges applying to evaluation of new substances for listed medicinesNew guidelines and mandatory requirements for listed medicines ingredients have come into effect on 1 February 2023.
- NewsPharmacovigilance Inspection Program Risk Assessment SurveyThe Pharmacovigilance Inspection Program (PVIP) Risk Assessment Survey is now open until 18 December 2022 for medicine sponsors to complete.